18 results
8-K
EX-10.1
ARVN
Arvinas Inc
27 Nov 23
Arvinas Announces Oversubscribed $350 Million Private Placement
7:11am
set forth herein or in the engagement letter, dated November 15, 2023, between the Company and BofA Securities, Inc. or in the engagement letter, dated … November 15, 2023, between the Company and Goldman Sachs & Co. LLC (together, the “Engagement Letters”); (2) shall be liable for any improper payment
S-3ASR
EX-1.2
ARVN
Arvinas Inc
7 Nov 23
Automatic shelf registration
5:24pm
to such employee’s employment or independent contractor’s engagement with the Company or actions undertaken while employed or engaged with the Company
8-K
EX-1.1
af1n08 gnp
6 Aug 21
Entry into a Material Definitive Agreement
4:09pm
8-K
EX-10.1
r6wl3401htadimzzdu
22 Jul 21
Arvinas and Pfizer Announce Global Collaboration to Develop and Commercialize PROTAC® Protein
7:30am
8-K
EX-10.2
sfbppzqe8x
22 Jul 21
Arvinas and Pfizer Announce Global Collaboration to Develop and Commercialize PROTAC® Protein
7:30am
8-K
EX-1.1
gzckp7xmtjnke6
18 Dec 20
Arvinas, Inc. Announces Pricing of $400 Million Public Offering of Common Stock
6:30am
8-K
EX-1.1
ufm 94bs14
12 Nov 19
Arvinas, Inc. Announces Pricing of Public Offering of Common Stock
4:02pm
DEF 14A
2ddiz
12 Apr 19
Definitive proxy
5:02pm
DRS/A
hhruap4m rw3m4gyv2s0
2 Aug 18
Draft registration statement (amended)
12:00am
DRS
kjizof6w4t
22 Jun 18
Draft registration statement
12:00am
- Prev
- 1
- Next